Literature DB >> 16573240

Entry of protein toxins into mammalian cells by crossing the endoplasmic reticulum membrane: co-opting basic mechanisms of endoplasmic reticulum-associated degradation.

J M Lord1, L M Roberts, W I Lencer.   

Abstract

The catalytic polypeptides of certain bacterial and plant protein toxins reach their substrates in the cytosol of mammalian cells by retro-translocation from the endoplasmic reticulum (ER). Emerging evidence indicates that these proteins subvert the ER-associated protein degradation (ERAD) pathway that normally removes misfolded or unassembled proteins from the ER, to achieve retrotranslocation. Upon entering the ER lumen, the toxins are unfolded to be perceived as ERAD substrates. Toxins that retro-translocate from the ER have an unusually low lysine content to avoid ubiquitin-mediated proteasomal degradation. This allows the exported toxins to refold into the proteasome-resistant, biologically active conformation, and leads to cellular intoxication.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16573240     DOI: 10.1007/3-540-28007-3_7

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  43 in total

Review 1.  Endoplasmic reticulum-dependent redox reactions control endoplasmic reticulum-associated degradation and pathogen entry.

Authors:  Christopher P Walczak; Kaleena M Bernardi; Billy Tsai
Journal:  Antioxid Redox Signal       Date:  2012-01-30       Impact factor: 8.401

2.  Detection of toxin translocation into the host cytosol by surface plasmon resonance.

Authors:  Michael Taylor; Tuhina Banerjee; Neyda VanBennekom; Ken Teter
Journal:  J Vis Exp       Date:  2012-01-03       Impact factor: 1.355

3.  AGAP2 regulates retrograde transport between early endosomes and the TGN.

Authors:  Yoko Shiba; Winfried Römer; Gonzalo A Mardones; Patricia V Burgos; Christophe Lamaze; Ludger Johannes
Journal:  J Cell Sci       Date:  2010-06-15       Impact factor: 5.285

4.  Conformational instability of the cholera toxin A1 polypeptide.

Authors:  Abhay H Pande; Patricia Scaglione; Michael Taylor; Kathleen N Nemec; Summer Tuthill; David Moe; Randall K Holmes; Suren A Tatulian; Ken Teter
Journal:  J Mol Biol       Date:  2007-10-16       Impact factor: 5.469

5.  Receptor-mediated phagocytosis elicits cross-presentation in nonprofessional antigen-presenting cells.

Authors:  Alessandra Giodini; Christoph Rahner; Peter Cresswell
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-13       Impact factor: 11.205

6.  Structural and functional interactions between the cholera toxin A1 subunit and ERdj3/HEDJ, a chaperone of the endoplasmic reticulum.

Authors:  Shane Massey; Helen Burress; Michael Taylor; Kathleen N Nemec; Supriyo Ray; David B Haslam; Ken Teter
Journal:  Infect Immun       Date:  2011-08-15       Impact factor: 3.441

7.  (S)-N-Methyldihydroquinazolinones are the Active Enantiomers of Retro-2 Derived Compounds against Toxins.

Authors:  Neetu Gupta; Valérie Pons; Romain Noël; David-Alexandre Buisson; Aurélien Michau; Ludger Johannes; Daniel Gillet; Julien Barbier; Jean-Christophe Cintrat
Journal:  ACS Med Chem Lett       Date:  2013-12-04       Impact factor: 4.345

8.  cAMP-Independent Activation of the Unfolded Protein Response by Cholera Toxin.

Authors:  Tuhina Banerjee; Aby Grabon; Michael Taylor; Ken Teter
Journal:  Infect Immun       Date:  2021-01-19       Impact factor: 3.441

9.  Folding-competent and folding-defective forms of ricin A chain have different fates after retrotranslocation from the endoplasmic reticulum.

Authors:  Shuyu Li; Robert A Spooner; Stuart C H Allen; Christopher P Guise; Graham Ladds; Tina Schnöder; Manfred J Schmitt; J Michael Lord; Lynne M Roberts
Journal:  Mol Biol Cell       Date:  2010-06-02       Impact factor: 4.138

10.  Ricin A-chain requires c-Jun N-terminal kinase to induce apoptosis in nontransformed epithelial cells.

Authors:  Amanda E Jetzt; Ju-Shun Cheng; Nilgun E Tumer; Wendie S Cohick
Journal:  Int J Biochem Cell Biol       Date:  2009-08-18       Impact factor: 5.085

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.